Submission on Pharmac proposal to fund bortezomib for Waldenström's macroglobulinemia

Rare Disorders NZ supports the widening of access to Bortezomib for people with Waldenström's macroglobulinemia (WM), but note that there are many other unfunded options for WM that the patient community and their clinicians need access to in order to best manage this disease.

We see that in this proposal Pharmac has identified that patient advocates and clinicians have advised Pharmac that there are other, more effective, treatments that they would like funded. This includes both ibrutinib and Zanubrutinib for which Pharmac has received funding applications for for the treatment of WM.

Read the full submission here.